GGA
VRTX icon

Granite Group Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Granite Group Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,138
Closed -$476K – 98
2024
Q1 		$476K Hold
1,138
– – 0.32% 52
2023
Q4 		$472K Buy
+1,138
New +$420K 0.33% 48

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Granite Group Advisors's VRTX Position: Q2 2024 in Review

Granite Group Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 1,138 shares — an estimated $476K sold.

Granite Group Advisors first reported a position in VRTX in Q4 2023 and held it in 2 quarters. The position peaked at $476K in Q1 2024. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Granite Group Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Granite Group Advisors sold 1,138 Vertex Pharmaceuticals shares in Q2 2024, an estimated $476K.
  • Granite Group Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Granite Group Advisors's Vertex Pharmaceuticals position peaked at $476K in Q1 2024.
  • 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Granite Group Advisors's 13F filing for Q2 2024, filed 23 Jul 2024.